Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

Julia A Gaebler 1
Gerardo Soto-Campos 2
Peter Alperin 2
Marc Cohen 2
Amy Blickensderfer 1
Matthew Wintle 1
David Maggs 1
Byron Hoogwerf 3
Jenny Han 1
Richard Pencek 1
Barbara Peskin 2

1Amylin Pharmaceuticals, Inc, San Diego CA, 2Archimedes Inc, San Francisco CA, 3Eli Lilly and Company, Indianapolis, IN, USA

Background: Patients with type 2 diabetes (T2DM) are at risk of long-term vascular complications. In trials, exenatide once weekly (ExQW), a GLP-1R agonist, improved glycemia, weight, blood pressure (BP), and lipids in patients with T2DM. We simulated potential effects of ExQW on vascular complications, survival, and medical costs over 20 years versus standard therapies.

Patients and methods: The Archimedes model was used to assess outcomes for ~25,000 virtual patients with T2DM (NHANES 1999–2006 [metformin ± sulfonylureas, age 57 years, body mass index 33 kg/m², weight 94 kg, duration T2DM 9 years, hemoglobin A1c [A1C] 8.1%]). The effects of three treatment strategies were modeled and compared to moderate-adherence insulin therapy: advancement to high-adherence insulin at A1C $8% (treat to target A1C, 7%) and addition of pioglitazone (PIO) or ExQW from simulation start. ExQW effects on A1C, weight, BP, and lipids were modeled from clinical trial data. Costs, inflated to represent 2010 $US, were derived from Medicare data, Drugstore.com, and publications. As ExQW was investigational, we omitted ExQW, PIO, and insulin pharmacy costs.

Results: By year 1, ExQW treatment decreased A1C (~1.5%), weight (~2 kg), and systolic BP (~5 mmHg). PIO and high-adherence insulin decreased A1C by ~1%, increased weight, and did not affect systolic BP. After 20 years, A1C was ~7% with all strategies. ExQW decreased rates of cardiovascular and microvascular complications more than PIO or high-adherence insulin versus moderate-adherence insulin. Over 20 years, ExQW treatment resulted in increased quality-adjusted life-years (QALYs) of ~0.3 years/person and cost savings of $469/life-year versus moderate adherence insulin. For PIO or high-adherence insulin, QALYs were virtually unchanged, and costs/life-year versus moderate-adherence insulin increased by $69 and $87, respectively.

Conclusions: This long-term simulation demonstrated that ExQW treatment may decrease rates of cardiovascular and some microvascular complications of T2DM. Increased QALYs, and decreased costs were also projected.

Keywords: diabetes, modeling, exenatide, pioglitazone, insulin, cardiovascular risk

Background

The incidence of diabetes and associated health problems continues to increase in the United States. 1,2 In 2010, approximately 25.6 million adults, or 11.3% of the adult (age ≥ 20 years) population in the United States had some form of diabetes, diagnosed or otherwise; 90% to 95% of the cases were type 2 diabetes mellitus (T2DM). 3 These patients are at long-term risk of cardiovascular events such as coronary heart disease.
improves glycemic control by enhancing glucose-dependent secretion of insulin, suppressing appetite, inhibiting postprandial glucagon secretion, and slowing gastric emptying. The twice-daily formulation (ExBID) is currently used to improve glycemic control in patients with T2DM. A once-weekly formulation (ExQW) is currently approved in the European Union and in the United States. In clinical studies, ExQW treatment resulted in reductions in hemoglobin A1c (A1C) and weight as well as in cardiovascular risk factors such as BP and lipids in patients with T2DM.

In the absence of long-term data on the effects of ExQW, we used the Archimedes model to assess the potential effects of ExQW, pioglitazone (PIO), and high-adherence insulin compared to moderate-adherence insulin on the incidence of cardiovascular and microvascular outcomes, on life-years, and on costs over 20 years in a cohort of patients with T2DM derived from the National Health and Nutrition Examination Survey (NHANES) 1999–2006.

**Patients and methods**

**Description of Archimedes model**

The Archimedes model simulates human physiology, disease progression, and health care delivery using an integrated model to describe the interactions of diseases, disease complications, various treatments, and health care guidelines as well as measures of quality of life and cost. Using differential equations maintains the continuous nature of biological variables, time, and their interactions. Diseases, and their respective treatments, are modeled at the clinical level. The model includes the effects of diabetes and other diseases, and incorporates patient and provider behaviors, office visits and hospital admissions, tests and treatments, care delivery protocols, performance and compliance, utilization, and costs. The model has been validated against a number of major clinical trials, including trials of diabetes management and treatment.

**Description of simulation strategies**

We designed simulation strategies to follow four hypothetical cohorts of patients with T2DM on background metformin ± sulfonylureas (SFU): (1) moderate-adherence insulin, (2) high-adherence insulin, and initiation at simulation start of (3) PIO or (4) ExQW. All strategies treated to a target A1C of 7%, but insulin was not initiated until A1C reached 8%. All strategies were identical with respect to general patient care guidelines and treatment goals, and concomitant diabetes treatments. Finally, all strategies maintained metformin therapy throughout the course of the 20-year simulation, and terminated SFU treatment when insulin was initiated. Adherence to insulin was set to 76% in the moderate-adherence insulin strategy, and 100% in the high-adherence insulin strategy, to be more competitive with PIO and ExQW. Based on queries of the IMS Health database for PIO and ExBID, we assumed that 14% of patients treated with PIO and 21% of patients treated with ExQW would remain on therapy after insulin was initiated.

The simulation population was derived from NHANES 1999–2006 and was reflective of patients with T2DM who had an A1C of 7%–11%, were 18–80 years old, were currently taking metformin with or without concomitant SFU, did not use insulin, and did not have end-stage renal disease. The simulation was run for 20 years with results reported annually; results at 5, 10, and 20 years are reported here.

**Outcomes**

The primary outcome of the four simulation strategies was their effect on prevention or delay of long-term cardiovascular disease and other diabetic complications. We also directly examined the impact on short-term (1-year) biomarker changes (eg, A1C, BP, lipids, weight) for each treatment strategy to ensure that data from the simulated and actual clinical trial populations were not substantially different. Cardiovascular disease outcomes included major adverse cardiovascular events (MACE- a composite
measure including MI, stroke, and CHD death), and individual measures of MI, stroke, CHD death, and congestive heart failure (CHF). Microvascular complications of diabetes included macrolaluminuria, end-stage renal disease (ESRD), macular edema, blindness, foot ulcer, and lower extremity amputation. All-cause death was also assessed.

Other outcomes included life-years (LYs), quality-adjusted LYs (QALYs), direct medical costs, and numbers needed-to-treat (NNT). The cost of health outcomes included the medical costs of hospital admissions, doctors’ visits, procedures, medications other than study medications, and tests. Inpatient, outpatient, ambulatory, and treatment costs were based primarily on Medicare charges. All costs were inflated to represent 2010 US dollars. Cost effectiveness was calculated using standard methods.23 Since ExQW was investigational at the time of this analysis, the costs of insulin, PIO, and ExQW treatments were not included in the calculations and we conducted a cost consequence analysis. QALYs were calculated as the sum of time spent in various health states, discounted by disutility scores associated with the state’s corresponding conditions.24 The model scanned each (virtual) patient’s medical record and applied disutility discounts associated with specific diagnoses. NNT was computed as in Altman et al.25

**ExQW model**

The ExQW model was constructed using data from four phase III clinical trials of ExQW treatment. Data from DURATION-1 (104 weeks),14 DURATION-2 (52 weeks),15 DURATION-3 (26 weeks),12 and DURATION-5 (26 weeks)13 were used to quantify the effect of ExQW on A1C, weight, BP, total cholesterol (TC), and triglycerides (TG). Data points from the trials for a given variable (eg, weight) were pooled, and the locally-weighted scatterplot smoothing (LOESS) technique was used to fit contours to the resulting aggregation, modeling the change from baseline as a function of time and baseline value.26 In the absence of long-term clinical trial data at the time of data analysis, no further change in effect was modeled for ExQW after 2 years, although the simulation included changes resulting from natural biomarker drift (eg, the effect of aging) and changes due to background patient care. Additionally, no direct effects on disease progression were modeled, just the effect of treatment on A1C, weight, BP, TC, and TG. For initial biomarkers values at normal levels, we assumed no effect of ExQW. Only ExQW was newly modeled for this work; models for PIO and insulin were already included in the Archimedes model.18

**Results**

**Demographics, biomarker trajectories, and medication use**

The simulated population was derived from NHANES in order to create a sample representative of patients meeting the inclusion criteria (18–80 years old, T2DM, A1C 7%–11%, currently using metformin ± SFU, not yet taking insulin). Generally, patients in the simulation were similar to those in the ExQW trials, differing by <1 standard deviation (Table 1).

An initial assessment of biomarkers after 1 year of simulated treatment for all strategies showed results that were in line with expectations. A1C decreased by −1% in PIO- and high-adherence insulin-treated patients and decreased by −1.5% in ExQW-treated patients. Patients treated with both insulin strategies and PIO experienced modest initial increases in weight while ExQW-treated patients experienced a reduction in weight of −2 kg. In the PIO and high-adherence insulin strategies there was little change in systolic BP (SBP), while the ExQW strategy decreased SBP by ∼5 mmHg. Changes in lipid profiles were observed primarily in PIO- and ExQW-treated patients. In PIO-treated patients, TG decreased by 16.3% and TC, high-density lipoproteins (HDL), and low-density lipoproteins (LDL) increased by 3.4%, 12.4%, and 6.5%, respectively. In ExQW-treated patients, decreases of 6.5%, 15.8%, and 6.2% were observed in TC, TG, and LDL, respectively; HDL did not change.

At the end of the 20-year simulation, A1C was −7% for all three treatment strategies, which was an expected outcome given the treat-to-target aspect of the simulations (Figure 1A). After changes in the first year, weight gradually decreased and SBP gradually increased with all treatment strategies due to the natural progression of aging (Figure 1B and C). After initial changes, LDL gradually decreased in all treatment strategies; HDL and TG remained fairly constant. Total cholesterol also gradually declined in all treatment strategies over the simulation period, with the greatest decrease after 20 years seen in EQW-treated patients (Figure 2).

As the simulation progressed, patients’ use of insulin and other background medications changed based on the level of control for a given biomarker. In all strategies, as patients reached an A1C of 8%, insulin treatment was initiated. By the end of the 20-year simulation, 55%, 82%, 29%, and 21% of patients in the moderate-adherence insulin, high-adherence
insulin, PIO, and ExQW arms, respectively, had initiated insulin use. The marked drop in the percentage of patients transitioning to insulin observed in the PIO and ExQW arms provided an indication of the effect of these agents on glycemic control. The percentage of patients using antihypertensive agents and statins increased over time for all treatment strategies (≈20% to 22% antihypertensives, ≈18% to 25% statins), but the increase in patients using these medications was slightly lower in ExQW-treated patients (≈20% antihypertensives, ≈18% statins). The decreased use of antihypertensives in ExQW-treated patients was due to the decrease in SBP. Statin use also mirrored the effect of treatments on LDL, increasing in PIO-treated patients and decreasing slightly in ExQW-treated patients relative to the insulin arms.

**Effect on health outcomes**

The effect of the four strategies on biomarkers translated to beneficial changes in overall long-term clinical health outcomes in the model. The event rates for MACE, components of MACE, and microvascular complications commonly associated with diabetes generally decreased for the three treatment arms relative to moderate-adherence insulin (Figure 3). For most health outcomes, ExQW decreased the event rate to a greater degree than did PIO and high-adherence insulin by virtue of its greater effect on A1C, weight, BP, and lipids. All-cause death decreased for all treatments compared to moderate-adherence insulin, but was statistically significant only for patients treated with ExQW (Figure 3). These decreases were pronounced at 20 years and most were seen as early as 5 and 10 years.

**Effects on LYS, QALYs, and costs**

At 5, 10, and 20 years, ExQW was associated with increased LYS and lower direct medical costs than moderate-adherence insulin, high-adherence insulin, and PIO strategies. Costs calculated did not include the cost of the treatments insulin, PIO, and ExQW. These differences resulted in an average cost/LY benefit of over $400 ($409–$469) relative to control (Table 2).

ExQW increased QALYs more than all other treatments, an effect that was observed at 5 years and continued to 20 years. After 20 years of treatment, QALYs were 13.72, 13.52, 13.46, and 13.44 per initial person for ExQW, high-adherence insulin, PIO and moderate-adherence insulin, respectively. Over 20 years, these changes translated into increases in QALYs for ExQW-treated patients of ∼3 months versus moderate-adherence insulin and PIO, and of ∼2.4 months versus high-adherence insulin (Figure 4).

**Numbers needed-to-treat (NNTs)**

ExQW required substantially fewer patients to be treated to avoid a single event than the high-adherence insulin and PIO strategies relative to moderate-adherence insulin (Table 3).

---

**Table 1** Baseline characteristics of the simulation and DURATION trials populations

|                      | Simulation (SD) | NHANES* | DURATION clinical trials – ExQW arm |
|----------------------|-----------------|---------|-------------------------------------|
|                      | Study 1         | Study 2 | Study 3 | Study 5 |
| Sample size          | 24,878          | 303     | 148     | 160     | 233     | 123     |
| Age, year            | 57.3 (12.5)     | 58      | 55      | 55      | 58      | 58      |
| Gender, % male       | 51.3            | 46      | 55      | 56      | 52      | 55      |
| BMI, kg/m²           | 33.1 (6.5)      | 33      | 35      | 32      | 32      | 33      |
| Weight, kg           | 93.6 (21.3)     | 94      | 102     | 89      | 91      | 94      |
| SBP, mmHg            | 127.7 (16.0)    | 132     | 128     | 126     | 135     | 128     |
| DBP, mmHg            | 72.3 (11.9)     | 71      | 78      | –       | –       | 81      |
| FPG, mg/dL           | 177.3 (33.5)    | 176     | 173     | 166     | 178     | 168     |
| A1C, %               | 8.1 (0.9)       | 8.1     | 8.3     | 8.6     | 8.3     | 8.4     |
| TC, mg/dL            | 198.4 (47.8)    | 195     | 174     | 174     | 186     | 196     |
| HDL, mg/dL           | 48.2 (14.7)     | 44      | 44      | 42.5    | 46      | 46      |
| LDL, mg/dL           | 111.1 (40.4)    | 107     | 92      | 104     | 104     | 120     |
| TG, mg/dL            | 197.6 (146.2)   | 225     | 167a    | 168a    | 164a    | 158b    |
| Creatinine, mg/dL    | 0.89 (0.20)     | 0.83    | –       | –       | –       | –       |
| Diabetes duration, year | 9.0 (8.4)   | 9.6     | 7       | 6       | 8       | 7       |
| Smokers, %           | 19.1            | 18.1    | –       | –       | –       | –       |
| History of myocardial infarction, % | 7.1     | 8.1    | –       | –       | –       | –       |
| History of stroke, % | 3.4             | 5.4     | –       | –       | –       | –       |
| History of CHF, %    | 4.8             | 4.7     | –       | –       | –       | –       |

Notes: Subjects fulfilling simulation inclusion/exclusion criteria; *data are geometric, rather than arithmetic, means.

Abbreviations: BMI, body mass index; CHF, congestive heart failure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoproteins; LDL, low-density lipoproteins; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglycerides; creatinine sample is serum.
Discussion

Modeling of health and economic outcomes allows an estimation of potential effects of new treatments with insufficient long-term data. This simulation provided evidence for the effectiveness of ExQW compared with insulin or PIO for preventing the cardiovascular complications, microvascular complications, and death associated with diabetes over 20 years of treatment.

Biomarkers such as A1C, weight, blood pressure, and lipids are associated with poor long-term cardiovascular health if not kept within normal ranges. Clinical trial data have shown that ExQW decreases these biomarkers, but the
Figure 2 Changes in total cholesterol (A), high- (B) and low-density (C) lipoproteins, and triglycerides (D) over 20 years of simulated treatment with high-adherence insulin, PIO, and ExQW versus moderate-adherence insulin.

Abbreviations: ExQW, exenatide once weekly; PIO, pioglitazone.

Data are short-term and limited to controlled clinical trial settings. Our simulation indicated that the effect of ExQW on improved glycemic control and cardiovascular biomarkers was associated with reduced cardiovascular event rates over 20 years. However, we note that the existence of a clinically-significant and positive relationship between glycemic control and cardiovascular event rates has been variable in a number of prospective trials.\(^{27,28}\) The MACE composite event rate, including MI, stroke, and CHD death, decreased with all treatments compared with moderate-adherence insulin, but patients treated with ExQW achieved the lowest rates.

All treatments in the simulation improved glycemic control but, as with cardiovascular risk factors, after 20 years, ExQW treatment reduced the risk of microvascular complications more than did high-adherence insulin or PIO. By design, all patients in the model were treated to target (A1C = 7%), and all strategies reduced the microvascular complications of diabetes. Many of these microvascular complications are also subject to the effects of weight and blood pressure. For example, macroalbuminuria, a precursor of serious renal complications, is affected by glycemic control as well as blood pressure.\(^{29,30}\) ExQW reduced macroalbuminuria by \(\sim 40\%\), while high-adherence insulin and PIO reduced macroalbuminuria event rates by \(\sim 16\) and \(15\%\), respectively. Development of two earlier-stage retinal complications of diabetes, proliferative diabetic retinopathy (PDR, data not shown) and macular edema, is governed to a large extent by glycemic control and blood pressure.\(^{29,30}\) The event rates of PDR and macular edema were decreased more in patients treated with ExQW than in patients treated with PIO and high-adherence insulin. However, the treatment strategies had only a small and similar effect on the very late stage complication of total blindness. Lower extremity amputation, driven by A1C, was similar across all therapies compared with moderate-adherence insulin.
Figure 3 Changes relative to moderate-adherence insulin in Kaplan-Meier event rates of cardiovascular and microvascular complications of diabetes after 20 years of simulated treatment with high-adherence insulin, PIO, and ExQW.

Notes: Negative values represent improvements over moderate-adherence insulin. All differences are statistically significant at the 5% level with these exceptions: for myocardial infarction and coronary heart disease death, PIO and ExQW are not significantly different; for stroke, bilateral blindness, and all-cause death, high-adherence insulin and PIO do not significantly differ from moderate-adherence insulin; for congestive heart failure, high-adherence insulin and ExQW do not differ significantly from moderate-adherence insulin; for macroalbuminuria, high-adherence insulin and PIO do not significantly differ; for ESRD, PIO does not significantly differ from high-adherence insulin; for foot ulcer and lower extremity amputation, high-adherence insulin, PIO, and ExQW do not differ amongst themselves, but all are significantly different from moderate-adherence insulin.

Abbreviations: ExQW, exenatide once weekly; PIO, pioglitazone.

Table 2 Total life-years and costs (undiscounted) per initial person for high-adherence insulin, PIO, and ExQW vs moderate-adherence insulin after 5, 10, and 20 years of treatment

| Simulation strategy | Total life years | Total costs US$ 2010 | Difference vs moderate-adherence insulin |
|---------------------|-----------------|----------------------|----------------------------------------|
|                     |                 | Life years | Cost | Cost/life years |
| 5 years             |                 |           |     |               |
| Moderate-adherence insulin | 4.77 | $36,568 | – | – |
| High-adherence insulin | 4.77 | $36,861 | 0.004 | $293 | $56 |
| PIO | 4.76 | $36,153 | –0.003 | –$415 | –$82 |
| ExQW | 4.78 | $34,739 | 0.016 | –$1,829 | –$409 |
| 10 years            |                 |           |     |               |
| Moderate-adherence insulin | 9.03 | $75,703 | – | – |
| High-adherence insulin | 9.05 | $76,492 | 0.016 | $789 | $73 |
| PIO | 9.03 | $75,292 | –0.005 | –$411 | –$41 |
| ExQW | 9.10 | $72,104 | 0.064 | –$3,600 | –$455 |
| 20 years            |                 |           |     |               |
| Moderate-adherence insulin | 15.80 | $154,087 | – | – |
| High-adherence insulin | 15.87 | $156,193 | 0.075 | $2,106 | $87 |
| PIO | 15.81 | $155,281 | 0.010 | $1,195 | $69 |
| ExQW | 16.06 | $149,137 | 0.264 | –$4,950 | –$469 |

Notes: Moderate-adherence insulin, treatment with insulin, initiated once glycemic control lapsed, usually when A1C >8.0%, with adherence set to 76%.

Abbreviations: ExQW, exenatide once weekly; PIO, pioglitazone.
insulin (~15% reduction), since all therapies treated to an A1C target of 7%. Finally, treatment with ExQW had a small, but significant, improvement over treatment with PIO or high-adherence insulin in reducing all-cause death. The improvements in health outcomes had substantial economic benefits. After 20 years of treatment, QALYs increased and total medical costs decreased for patients treated with ExQW compared to all other strategies. These improvements with ExQW treatment were observed after 5 years and increased as the simulation progressed. Cost savings were also observed with PIO treatment at 5 and 10 years, but were markedly less than for ExQW, and the savings disappeared entirely by simulation end.

Limitations and assumptions
These findings were based on a mathematical model and as such were subject to the assumptions used to create it. The ExQW model was derived from four clinical trials, each with limited data, and assumed that the effects of ExQW treatment would remain constant after year 2, that ExQW treatment would continue indefinitely unless advancement to insulin occurred, and that there were no adverse effects associated with ExQW treatment. The adverse effects that were modeled included hypoglycemia for insulin and SFU treatment and CHF for PIO treatment, both well-documented for the respective treatments. Patients were assumed to be 100% compliant to insulin, PIO, and ExQW in the high-adherence insulin, PIO, and ExQW treatment strategies, respectively, a less than realistic scenario. However, effects for more realistic compliance levels can be estimated by interpolating results between the moderate-adherence insulin and the other treatment arms. The simulation model did include the cost of treatment for diseases/conditions such as high blood pressure and high cholesterol; it did not include any treatment costs for insulin, PIO, and ExQW. Finally, the impact of known or suspected biomarkers for cardiovascular and microvascular complications such as measures of inflammation, oxidation, or fat-derived cytokines and the effects of each of the glucose-lowering agents on these markers were not included in the model.

Conclusion
The simulation of ExQW treatment in patients with T2DM for 20 years indicates that the treatment may decrease the complications associated with the morbidity and mortality.

Table 3 Numbers needed-to-treat versus moderate-adherence insulin to avoid a single cardiovascular event

| Outcome                      | Treatment strategy | Number needed-to-treat versus moderate-adherence insulin |
|------------------------------|--------------------|---------------------------------------------------------|
|                              |                    | 5 years | 10 years | 20 years |
| MACE composite               | High-adherence insulin | 341     | 128      | 91       |
|                              | PIO                | 149     | 59       | 43       |
|                              | ExQW               | 74      | 38       | 29       |
| Myocardial infarction        | High-adherence insulin | 345     | 126      | 84       |
|                              | PIO                | 142     | 58       | 38       |
|                              | ExQW               | 94      | 47       | 33       |
| Stroke                       | High-adherence insulin | >1,000  | >1,000   | >1,000   |
|                              | PIO                | >1,000  | 818      | 413      |
|                              | ExQW               | 295     | 142      | 85       |
| Coronary heart disease death | High-adherence insulin | >1,000  | 429      | 236      |
|                              | PIO                | >1,000  | 257      | 116      |
|                              | ExQW               | 407     | 197      | 95       |

Abbreviations: MACE, major adverse cardiovascular event and is a composite measure including myocardial infarction, stroke, and coronary heart disease death; moderate adherence insulin, treatment with insulin, initiated once glycemic control lapsed, usually when A1C > 8.0%, with adherence set to 76%.
of T2DM, including MACE and many microvascular complications. ExQW treatment was also associated with a decrease in the cost of management of diabetes and its complications and an increase in QALYs. Simulations using ExQW data gathered beyond 2 years and incorporating adverse event data will further refine these observations. Validation through long-term trials such as the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial (NCT01144338) is also needed.

Acknowledgment
We wish to acknowledge Susan Strobel, PhD of SciComm LLC for assistance with manuscript preparation (funded by Amylin Pharmaceuticals, Inc).

Disclosure
Julia A. Gaebler, Amy Blickensderfer, Matthew Wintle, David Maggs, Jenny Han, and Richard Pencek were employees and shareholders of Amylin Pharmaceuticals, Inc. at the time this study was conducted. Gerardo Soto-Campos, Peter Alperin, Marc Cohen, and Barbara Peskin received research support from Amylin Pharmaceuticals, Inc.; at the time this study was conducted, all were employees of Archimedes Inc. Byron Hoogwerf is an employee of Eli Lilly and Company.

References
1. Center for Disease Control and Prevention. Diabetes data and trends: national surveillance data – number (in millions) of civilian, non-institutionalized adults with diagnosed diabetes, United States, 1980–2009. c2011 [updated March 30, 2011]. Available from: http://www.cdc.gov/diabetes/statistics/prev/national-fgadults.htm. Accessed November 13, 2011.
2. Center for Disease Control and Prevention. Diabetes data and trends: national surveillance data – diabetes complications. c2011 [updated June 16, 2011]. Available from: http://www.cdc.gov/diabetes/statistics/complications_national.htm. Accessed November 13, 2011.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. c2011 [Updated November 8, 2011]. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed November 13, 2011.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
5. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559.
6. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.
7. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114–126.
8. American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34 Suppl 1:S1–S61.
9. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem. 1992;267:7402–7405.
10. BYETTA® (exenatide) injection. Full prescribing information. c2010 [Revised September 2010; Amylin Pharmaceuticals Inc, San Diego, CA]. Available from: http://pi.lilly.com/us/byetta-pi.pdf. Accessed August 20, 2011.
11. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470–512.
12. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234–2243.
13. Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301–1310.
14. Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011;11:9.
15. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28:705–714.
16. Eddy D, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care. 2003;26:3102–3110.
17. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–264.
18. Alperin P, Soto-Campos G, Peskin B, et al. Understanding the effect of glycemic control on macrovascular outcomes in patients with diabetes using the Archimedes Model [abstract]. Diabetes. 2010;59:Abstract 879-P.
19. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375:1365–1374.
20. Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther. 1999;21:1045–1057.
21. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control. Diabetes Care. 2005;28:78–83.
22. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES). c2011. Available from: http://www.cdc.gov/nchs/nhanes.htm. Accessed June 23, 2011.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
24. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410–420.
25. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492–1495.
26. Cleveland WS, Grosse E, Shyu MJ. Local regression models. In: Chambers JM, Hastie T, editors. Statistical Models in S. NY: Chapman and Hall; 1992:309–376.
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2010;362:1279–1289.
28. Skyler JS, Bergenstal R, Alperin P, et al; for American Diabetes Association/American College of Cardiology Foundation/American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–192.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837–853.

30. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317:703–713.